IO Biotech announces results from Phase 2 trial of IO102-IO103

IO Biotech (IOBT) announced promising data from the Phase 2 basket trial of IO102-IO103, the company’s lead investigational therapeutic cancer vaccine candidate, in combination with Merck’s (MRK) anti-PD-1 therapy KEYTRUDA at the 2024 ESMO Congress in Barcelona from September 13-17. The presentation contained clinical and biomarker data from a cohort of patients with recurrent or metastatic squamous cell carcinoma of the head and neck with PD-L1 CPS greater than or equal to 20, contributing to the growing body of research supporting the potential clinical benefit of this combination regimen for these patients. The data from 18 efficacy evaluable patients demonstrated: Achievement of the primary endpoint – confirmed 44.4% overall response rate in a PD-L1 high population of patients with SCCHN irrespective of HPV status. An encouraging 6.6-month median progression-free survival. A 66.7% disease control rate. A safety profile consistent with previously reported data when combined with anti-PD-1 monotherapy. T-cell responses to both IO102 and IO103 were detected after treatment.